Use of AI in Clinical Research, Part 2
In Part 2, Amir Kalali, MD, Independent Consultant, continues the discussion with Luca Pani, MD, focusing on how AI could fundamentally transform CNS drug development by enabling deeper biological insight, patient enrichment, and real-world outcome assessment, while emphasizing the cultural resistance, regulatory transparency, ethical trust, and leadership readiness required for responsible adoption.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.